Gennex Lab.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE509C01026
  • NSEID:
  • BSEID: 531739
INR
8.87
-0.1 (-1.11%)
BSENSE

Nov 20

BSE+NSE Vol: 1.41 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 930938,
    "name": "Gennex Lab.",
    "stock_name": "Gennex Lab.",
    "full_name": "Gennex Laboratories Ltd",
    "name_url": "stocks-analysis/gennex-lab",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "8.87",
    "chg": -0.1,
    "chgp": "-1.11%",
    "dir": -1,
    "prev_price": "8.97",
    "mcapval": "218.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531739,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE509C01026",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "1.41 lacs",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/gennex-lab-930938-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Gennex Laboratories Ltd is Rated Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/gennex-laboratories-ltd-is-rated-sell-4266749",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/GennexLaborator_mojoScore_4266749.png",
        "date": "2026-11-18 10:11:06",
        "description": "Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 November 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Gennex Laboratories Ltd is Rated Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/gennex-laboratories-ltd-is-rated-sell-4253888",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/GennexLaborator_mojoScore_4253888.png",
        "date": "2026-11-06 10:11:34",
        "description": "Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 November 2026, providing investors with the most up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Gennex Laboratories Ltd is Rated Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/gennex-laboratories-ltd-is-rated-sell-4238701",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/GennexLaborator_mojoScore_4238701.png",
        "date": "2026-10-26 10:10:26",
        "description": "Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 October 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance."
      },
      {
        "title": "Gennex Laboratories Ltd is Rated Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/gennex-laboratories-ltd-is-rated-sell-4226582",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/GennexLaborator_mojoScore_4226582.png",
        "date": "2026-10-15 10:10:40",
        "description": "Gennex Laboratories Ltd is rated Sell by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 October 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Gennex Laboratories Ltd is Rated Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/gennex-laboratories-ltd-is-rated-sell-4213208",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/GennexLaborator_mojoScore_4213208.png",
        "date": "2026-10-04 10:10:27",
        "description": "Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 October 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Gennex Laboratories Ltd is Rated Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/gennex-laboratories-ltd-is-rated-sell-4202343",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/GennexLaborator_mojoScore_4202343.png",
        "date": "2026-09-23 10:10:46",
        "description": "Gennex Laboratories Ltd is rated Sell by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "Gennex Laboratories Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/gennex-laboratories-ltd-downgraded-to-sell-amid-mixed-financial-and-technical-signals-4186037",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/GennexLaborator_mojoScore_4186037.png",
        "date": "2026-09-08 09:02:34",
        "description": "Gennex Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 7 September 2026. This change reflects a combination of deteriorating technical indicators, flat recent financial performance, and concerns over promoter share pledging, despite attractive valuation metrics and long-term market-beating returns."
      },
      {
        "title": "Gennex Laboratories Declines 6.12% Amid Valuation Reset and Technical Upgrade",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/gennex-laboratories-declines-612-amid-valuation-reset-and-technical-upgrade-4183581",
        "imagepath": "",
        "date": "2026-09-05 14:06:59",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>31 Aug:</strong> Stock opens at ₹12.62, down 2.25% amid broader market weakness</p>\n                    <p><strong>1 Sep:</strong> Mojo grade upgraded to Hold on improved technicals and valuation</p>\n                    <p><strong>2-3 Sep:</strong> Continued price decline with subdued volumes</p>\n                    <p><strong>4 Sep:</strong> Price rebounds 2.71% to close at ₹12.12, Sensex gains 0.19%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">₹12.91</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div cla..."
      },
      {
        "title": "Gennex Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/gennex-laboratories-ltd-valuation-shifts-signal-renewed-price-attractiveness-4176645",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/GennexLaborator_valuationdot_4176645.png",
        "date": "2026-09-01 08:00:57",
        "description": "Gennex Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a very attractive grade, signalling a potential opportunity for investors in the Pharmaceuticals & Biotechnology sector. This re-rating comes amid a backdrop of mixed sector valuations and a micro-cap status that warrants close attention."
      }
    ],
    "total": 42,
    "sid": "930938",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/gennex-laboratories-930938"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "17-Nov-2026",
      "details": "Pursuant to regulation 47 of SEBI (LODR) Regulations 2015 please find enclosed herewith Newspaper publication on Unaudited (Standalone and Consolidated) Financial Results for the Quarter and Half year ended September 30 2026 announced by the Board of Directors in its meeting held on Saturday November 14 2026. Financial results had been published in both Business Standard (English) and Saksham (Telugu - Local) on November 17 2026.",
      "source": "BSE"
    },
    {
      "caption": "Intimation Regarding Dissolution Of The Rights Issue Committee Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
      "datetime": "14-Nov-2026",
      "details": "Pursuant to Regulation 30 read with Schedule III of the SEBI (LODR) Regulations 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. November 14 2026 has approved the dissolution of the Rights Issue Committee with immediate effect i.e. November 14 2026.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Meeting Held Today I.E. 30Th September 2026",
      "datetime": "14-Nov-2026",
      "details": "1. Unaudited (Standalone and Consolidated) Financial Results for the Quarter and Half year ended September 30 2026 along with the Statement of Assets and Liabilities as at September 30 2026 and the Statement of Cash Flows for the half year ended September 30 2026 (annexed herewith);",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Gennex Laboratories Ltd has announced <strong>1:10</strong> stock split, ex-date: 14 Dec 09",
          "dt": "2009-12-14",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Gennex Laboratories Ltd has announced <strong>1:2</strong> rights issue, ex-date: 21 Jul 22",
          "dt": "2022-07-21",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Newspaper Publication

17-Nov-2026 | Source : BSE

Pursuant to regulation 47 of SEBI (LODR) Regulations 2015 please find enclosed herewith Newspaper publication on Unaudited (Standalone and Consolidated) Financial Results for the Quarter and Half year ended September 30 2026 announced by the Board of Directors in its meeting held on Saturday November 14 2026. Financial results had been published in both Business Standard (English) and Saksham (Telugu - Local) on November 17 2026.

Intimation Regarding Dissolution Of The Rights Issue Committee Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015

14-Nov-2026 | Source : BSE

Pursuant to Regulation 30 read with Schedule III of the SEBI (LODR) Regulations 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. November 14 2026 has approved the dissolution of the Rights Issue Committee with immediate effect i.e. November 14 2026.

Board Meeting Outcome for Meeting Held Today I.E. 30Th September 2026

14-Nov-2026 | Source : BSE

1. Unaudited (Standalone and Consolidated) Financial Results for the Quarter and Half year ended September 30 2026 along with the Statement of Assets and Liabilities as at September 30 2026 and the Statement of Cash Flows for the half year ended September 30 2026 (annexed herewith);

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

Gennex Laboratories Ltd has announced 1:10 stock split, ex-date: 14 Dec 09

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

Gennex Laboratories Ltd has announced 1:2 rights issue, ex-date: 21 Jul 22